super ace jff
We're going to jump in the wayback machine to 1975, for this fantastic Johnny Carson interview of Ronald Reagan, before the latter was elected President. Watch what the Gipper had to say about taxes and government: Listen carefully what Ronald Reagan had to say about government, taxes and inflation. pic.twitter.com/noCoESVSng He's correct. This is a fantastic video It really is. Thank goodness technology brought it to us. Why did ppl not like this man? Because (R)easons. He's describing the permanent bureaucracy here. "Deep State" players have only become more powerful in 44 years. Yes. All of it still amazingly relevant today. And Democrats will never admit that Reagan was ever this erudite. Never. "I think the answer to curing inflation is a balanced budget... Balancing the budget is like protecting your virtue - you have to learn to say No" ~ Ronald Reagan A great line. We would be better off with a hologram of this guy than our current President. Wow. Great stuff. That's a low bar, but yes. A shoe would be better than Joe Biden. The level of discourse on a nighttime comedy show was higher in the 1970s than any ‘serious’ show today. https://t.co/tXuS5bNnSZ Yes. And this writer can probably surmise Carson's political leanings, but you'd never know it from this clip. (Dick Cavett's show was also good for this sort of discourse). “We live in the only country where it takes more brains to figure out the tax than it does to make the income” https://t.co/w4ONGhYEIC Another great line. Every time you see the great white buffalo chip ( @SenWarren ) wail about taxing businesses and billionaires, she's actually advocating to tax YOU indirectly. She knows it, but she hopes you are too dumb to realize it. https://t.co/dxFHyP4M0m Exactly.PHILADELPHIA (AP) — The Philadelphia Phillies have no plans to pitch prized prospect Andrew Painter in spring training games as he recovers from Tommy John surgery. The 21-year-old Painter hurt his elbow during spring training in 2023 and had surgery that July 25 with Los Angeles Dodgers head team physician Dr. Neal ElAttrache. Painter was the 13th overall pick in the 2021 amateur draft and signed for a $3.9 million bonus. “He'll throw but not plan on pitching” in games, Phillies president of baseball operations Dave Dombrowski said Monday. “We're going to push the innings back.” Dombrowski said Painter will build up at some point in the minor leagues and could make his major league debut at some point in the summer. Painter made six starts and allowed four runs in the Arizona Fall League. He struck out 18 batters in 15 2/3 innings after he sat out each of the last two seasons. Painter sprinted through Philadelphia’s system in 2022, going 6-2 with a 1.48 ERA in 26 appearances spread across two Class A teams and Double-A Reading. AP MLB: https://apnews.com/hub/MLB
Shopping on Temu can feel like playing an arcade game. Instead of using a joystick-controlled claw to grab a toy, visitors to the online marketplace maneuver their computer mouses or cellphone screens to browse colorful gadgets, accessories and trinkets with prices that look too good to refuse. A pop-up spinning wheel offers the chance to win a coupon. Rotating captions warn that a less than $2 camouflage print balaclava and a $1.23 skeleton hand back scratcher are “Almost sold out.” A flame symbol indicates a $9.69 plush cat print hoodie is selling fast. A timed-down selection of discounted items adds to the sense of urgency. Pages from the Shein website, left, and from the Temu site, right. Richard Drew, Associated Press Welcome to the new online world of impulse buying, a place of guilty pleasures where the selection is vast, every day is Cyber Monday, and an instant dopamine hit is always just a click away. By all accounts, we’re living in an accelerating age for consumerism, one that Temu, which is owned by the Chinese e-commerce company PDD Holdings, and Shein, its fierce rival , supercharged with social media savvy and an interminable assortment of cheap goods, most shipped directly from merchants in China based on real-time demand. The business models of the two platforms, coupled with avalanches of digital or influencer advertising, have enabled them to give Western retailers a run for their money this holiday shopping season. A Christmas tree ornament purchased on Temu. Haleluya Hadero, Associated Press Software company Salesforce said it expects roughly one in five online purchases in the U.S., the United Kingdom, Australia and Canada to be made through four online marketplaces based or founded in Asia: Shein, Temu, TikTok Shop — the e-commerce arm of video-sharing platform TikTok — and AliExpress. Analysts with Salesforce said they are expected to pull in roughly $160 billion in global sales outside of China. Most of the sales will go to Temu and Shein, a privately held company which is thought to lead the worldwide fast fashion market in revenue. Lisa Xiaoli Neville, a nonprofit manager who lives in Los Angeles, is sold on Shein. The bedroom of her home is stocked with jeans, shoes, press-on nails and other items from the ultra-fast fashion retailer, all of which she amassed after getting on the platform to buy a $2 pair of earrings she saw in a Facebook ad. Neville, 46, estimates she spends at least $75 a month on products from Shein. A $2 eggshell opener, a portable apple peeler and an apple corer, both costing less than $5, are among the quirky, single-use kitchen tools taking up drawer space. She acknowledges she doesn’t need them because she “doesn’t even cook like that.” Plus, she’s allergic to apples. “I won’t eat apples. It will kill me,” Neville said, laughing. “But I still want the coring thing.” Listen now and subscribe: Apple Podcasts | Google Podcasts | Spotify | Stitcher | RSS Feed | SoundStack | All Of Our Podcasts Shein, now based in Singapore, uses some of the same web design features as Temu’s, such as pop-up coupons and ads, to persuade shoppers to keep clicking, but it appears a bit more restrained in its approach. Shein primarily targets young women through partnerships with social media influencers. Searching the company's name on video platforms turns up creators promoting Shein's Black Friday sales event and displaying the dozens of of trendy clothes and accessories they got for comparatively little money. But the Shein-focused content also includes videos of TikTokers saying they're embarrassed to admit they shopped there and critics lashing out at fans for not taking into account the environmental harms or potential labor abuses associated with products that are churned out and shipped worldwide at a speedy pace. Neville has already picked out holiday gifts for family and friends from the site. Most of the products in her online cart cost under $10, including graphic T-shirts she intends to buy for her son and jeans and loafers for her daughter. All told, she plans to spend about $200 on gifts, significantly less than $500 she used to shell out at other stores in prior years. “The visuals just make you want to spend more money,” she said, referring to the clothes on Shein's site. “They're very cheap and everything is just so cute.” Unlike Shein, Temu's appeal cuts across age groups and gender. The platform is the world’s second most-visited online shopping site, software company Similarweb reported in September. Customers go there looking for practical items like doormats and silly products like a whiskey flask shaped like a vintage cellphone from the 1990s. Temu advertised Black Friday bargains for some items at upwards of 70% off the recommended retail price. Making a purchase can quickly result in receiving dozens of emails offering free giveaways. The caveat: customers have to buy more products. Despite their rise, Temu and Shein have proven particularly ripe for pushback. Last year, a coalition of unnamed brands and organizations launched a campaign to oppose Shein in Washington. U.S. lawmakers also have raised the possibility that Temu is allowing goods made with forced labor to enter the country. More recently, the Biden administration put forward rules that would crack down on a trade rule known as the de minimis exception, which has allowed a lot of cheap products to come into the U.S. duty-free. President-elect Donald Trump is expected to slap high tariffs on goods from China, a move that would likely raise prices across the retail world. Both Shein and Temu have set up warehouses in the U.S. to speed up delivery times and help them better compete with Amazon, which is trying to erode their price advantage through a new storefront that also ships products directly from China.Phillies have no plans to start pitching prospect Andrew Painter in spring training following injuryShopping on Temu can feel like playing an arcade game. Instead of using a joystick-controlled claw to grab a toy, visitors to the online marketplace maneuver their computer mouses or cellphone screens to browse colorful gadgets, accessories and trinkets with prices that look too good to refuse. A pop-up spinning wheel offers the chance to win a coupon. Rotating captions warn that a less than $2 camouflage print balaclava and a $1.23 skeleton hand back scratcher are “Almost sold out.” A flame symbol indicates a $9.69 plush cat print hoodie is selling fast. A timed-down selection of discounted items adds to the sense of urgency. Pages from the Shein website, left, and from the Temu site, right. Welcome to the new online world of impulse buying, a place of guilty pleasures where the selection is vast, every day is Cyber Monday, and an instant dopamine hit is always just a click away. By all accounts, we’re living in an accelerating age for consumerism, one that Temu, which is owned by the Chinese e-commerce company PDD Holdings, and Shein, its fierce rival , supercharged with social media savvy and an interminable assortment of cheap goods, most shipped directly from merchants in China based on real-time demand. The business models of the two platforms, coupled with avalanches of digital or influencer advertising, have enabled them to give Western retailers a run for their money this holiday shopping season. A Christmas tree ornament purchased on Temu. Software company Salesforce said it expects roughly one in five online purchases in the U.S., the United Kingdom, Australia and Canada to be made through four online marketplaces based or founded in Asia: Shein, Temu, TikTok Shop — the e-commerce arm of video-sharing platform TikTok — and AliExpress. Analysts with Salesforce said they are expected to pull in roughly $160 billion in global sales outside of China. Most of the sales will go to Temu and Shein, a privately held company which is thought to lead the worldwide fast fashion market in revenue. Lisa Xiaoli Neville, a nonprofit manager who lives in Los Angeles, is sold on Shein. The bedroom of her home is stocked with jeans, shoes, press-on nails and other items from the ultra-fast fashion retailer, all of which she amassed after getting on the platform to buy a $2 pair of earrings she saw in a Facebook ad. Neville, 46, estimates she spends at least $75 a month on products from Shein. A $2 eggshell opener, a portable apple peeler and an apple corer, both costing less than $5, are among the quirky, single-use kitchen tools taking up drawer space. She acknowledges she doesn’t need them because she “doesn’t even cook like that.” Plus, she’s allergic to apples. “I won’t eat apples. It will kill me,” Neville said, laughing. “But I still want the coring thing.” Shein, now based in Singapore, uses some of the same web design features as Temu’s, such as pop-up coupons and ads, to persuade shoppers to keep clicking, but it appears a bit more restrained in its approach. Shein primarily targets young women through partnerships with social media influencers. Searching the company's name on video platforms turns up creators promoting Shein's Black Friday sales event and displaying the dozens of of trendy clothes and accessories they got for comparatively little money. But the Shein-focused content also includes videos of TikTokers saying they're embarrassed to admit they shopped there and critics lashing out at fans for not taking into account the environmental harms or potential labor abuses associated with products that are churned out and shipped worldwide at a speedy pace. Neville has already picked out holiday gifts for family and friends from the site. Most of the products in her online cart cost under $10, including graphic T-shirts she intends to buy for her son and jeans and loafers for her daughter. All told, she plans to spend about $200 on gifts, significantly less than $500 she used to shell out at other stores in prior years. “The visuals just make you want to spend more money,” she said, referring to the clothes on Shein's site. “They're very cheap and everything is just so cute.” Unlike Shein, Temu's appeal cuts across age groups and gender. The platform is the world’s second most-visited online shopping site, software company Similarweb reported in September. Customers go there looking for practical items like doormats and silly products like a whiskey flask shaped like a vintage cellphone from the 1990s. Temu advertised Black Friday bargains for some items at upwards of 70% off the recommended retail price. Making a purchase can quickly result in receiving dozens of emails offering free giveaways. The caveat: customers have to buy more products. Despite their rise, Temu and Shein have proven particularly ripe for pushback. Last year, a coalition of unnamed brands and organizations launched a campaign to oppose Shein in Washington. U.S. lawmakers also have raised the possibility that Temu is allowing goods made with forced labor to enter the country. More recently, the Biden administration put forward rules that would crack down on a trade rule known as the de minimis exception, which has allowed a lot of cheap products to come into the U.S. duty-free. President-elect Donald Trump is expected to slap high tariffs on goods from China, a move that would likely raise prices across the retail world. Both Shein and Temu have set up warehouses in the U.S. to speed up delivery times and help them better compete with Amazon, which is trying to erode their price advantage through a new storefront that also ships products directly from China. Get the latest local business news delivered FREE to your inbox weekly.
Peripheral T Cell Lymphomas Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Celleron Therapeutics, Myeloid Therapeutics, Astex Pharma 12-23-2024 11:04 PM CET | Business, Economy, Finances, Banking & Insurance Press release from: ABNewswire (Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Peripheral T Cell Lymphomas pipeline constitutes 40+ key companies continuously working towards developing 40+ Peripheral T Cell Lymphomas treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The Peripheral T Cell Lymphomas Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. "Peripheral T Cell Lymphomas Pipeline Insight, 2024 [ https://www.delveinsight.com/sample-request/peripheral-t-cell-lymphomas-ptcl-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr ]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Peripheral T Cell Lymphomas Market. Some of the key takeaways from the Peripheral T Cell Lymphomas Pipeline Report: * Companies across the globe are diligently working toward developing novel Peripheral T Cell Lymphomas treatment therapies with a considerable amount of success over the years. * Peripheral T Cell Lymphomas companies working in the treatment market are HUYA Bioscience International, Applied Therapeutics, Autolus, Akeso Biopharma, Astex Pharmaceuticals, Secura Bio, Innate Pharma, Dizal Pharmaceutical, CSPC ZhongQi Pharmaceutical Technology, and others, are developing therapies for the Peripheral T Cell Lymphomas treatment * Emerging Peripheral T Cell Lymphomas therapies in the different phases of clinical trials are- HBI-8000, AT-104, Auto 5, AK 104, Tolinapant, Duvelisib, Lacutamab, AZD 4205, Mitoxantrone liposomal, and others are expected to have a significant impact on the Peripheral T Cell Lymphomas market in the coming years. * In December 2024, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") announced new data showcasing significant improvements in quality of life for patients with cutaneous T-cell lymphoma (CTCL) treated with lacutamab in the TELLOMAK Phase 2 clinical study. The findings were presented at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego, California. * In December 2024, Secura Bio, Inc. (Secura Bio), an integrated pharmaceutical company focused on the global development and commercialization of effective oncology therapies, presented two posters at the 2024 American Society of Hematology (ASH) Annual Meeting in San Diego, CA. The first poster showcased new data from the Company's Phase 2 PRIMO trial of duvelisib for treating relapsed/refractory (R/R) peripheral T-cell lymphoma (PTCL), while the second poster outlined the clinical design for the planned Phase 3 randomized trial of duvelisib in R/R nodal T-follicular helper cell lymphoma (TERZO Trademark ). Peripheral T Cell Lymphomas Overview Peripheral T-cell lymphomas (PTCL) are a diverse group of aggressive blood cancers that develop in T-cells, a type of white blood cell involved in immune function. Unlike other types of lymphoma, PTCL originates outside the bone marrow, typically in lymph nodes, spleen, or other tissues. Symptoms may include swollen lymph nodes, fever, weight loss, night sweats, and skin rashes. PTCL is rare and often more difficult to treat compared to other lymphomas. Treatment options may include chemotherapy, immunotherapy, stem cell transplants, and targeted therapies, depending on the specific subtype and stage of the disease. Get a Free Sample PDF Report to know more about Peripheral T Cell Lymphomas Pipeline Therapeutic Assessment- https://www.delveinsight.com/report-store/peripheral-t-cell-lymphomas-ptcl-pipeline-insight [ https://www.delveinsight.com/report-store/peripheral-t-cell-lymphomas-ptcl-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr ] Emerging Peripheral T Cell Lymphomas Drugs Under Different Phases of Clinical Development Include: * HBI-8000: HUYA Bioscience International * AT-104: Applied Therapeutics * Auto 5: Autolus * AK 104: Akeso Biopharma * Tolinapant: Astex Pharmaceuticals * Duvelisib: Secura Bio * Lacutamab: Innate Pharma * AZD 4205: Dizal Pharmaceutical * Mitoxantrone liposomal: CSPC ZhongQi Pharmaceutical Technology Peripheral T Cell Lymphomas Route of Administration Peripheral T Cell Lymphomas pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as * Subcutaneous * Intravenous * Oral * Intramuscular * Intra-tumoral * Molecule Type Peripheral T Cell Lymphomas Molecule Type Peripheral T Cell Lymphomas Products have been categorized under various Molecule types, such as * Monoclonal antibodies * Immunoglobulins * Small molecules * Pyrimidines * Proteins and Peptides * Product Type Peripheral T Cell Lymphomas Pipeline Therapeutics Assessment * Peripheral T Cell Lymphomas Assessment by Product Type * Peripheral T Cell Lymphomas By Stage and Product Type * Peripheral T Cell Lymphomas Assessment by Route of Administration * Peripheral T Cell Lymphomas By Stage and Route of Administration * Peripheral T Cell Lymphomas Assessment by Molecule Type * Peripheral T Cell Lymphomas by Stage and Molecule Type DelveInsight's Peripheral T Cell Lymphomas Report covers around 40+ products under different phases of clinical development like * Late-stage products (Phase III) * Mid-stage products (Phase II) * Early-stage product (Phase I) * Pre-clinical and Discovery stage candidates * Discontinued & Inactive candidates * Route of Administration Further Peripheral T Cell Lymphomas product details are provided in the report. Download the Peripheral T Cell Lymphomas pipeline report to learn more about the emerging Peripheral T Cell Lymphomas therapies [ https://www.delveinsight.com/sample-request/peripheral-t-cell-lymphomas-ptcl-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr ] Some of the key companies in the Peripheral T Cell Lymphomas Therapeutics Market include: Key companies developing therapies for Peripheral T Cell Lymphomas are - Celleron Therapeutics, Myeloid Therapeutics, Astex Pharmaceuticals, Citius Pharmaceuticals, Innate Pharma, Secura Bio, Genor Biopharma Co., Ltd., CerRx, Inc., Dizal Pharmaceuticals, Kura Oncology, Inc., Viracta Therapeutics, Autolus Therapeutics, Affimed Therapeutics, C4 Therapeutics, Kymera Therapeutics, Daiichi Sankyo, SciTech Development LLC, Sorrento Therapeutics, Bristol-Myers Squibb, Shanghai Yingli Pharmaceutical, Ono Pharmaceutical, and others. Peripheral T Cell Lymphomas Pipeline Analysis: The Peripheral T Cell Lymphomas pipeline report provides insights into * The report provides detailed insights about companies that are developing therapies for the treatment of Peripheral T Cell Lymphomas with aggregate therapies developed by each company for the same. * It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Peripheral T Cell Lymphomas Treatment. * Peripheral T Cell Lymphomas key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. * Peripheral T Cell Lymphomas Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. * Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Peripheral T Cell Lymphomas market. The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc. Download Sample PDF Report to know more about Peripheral T Cell Lymphomas drugs and therapies [ https://www.delveinsight.com/sample-request/peripheral-t-cell-lymphomas-ptcl-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr ] Peripheral T Cell Lymphomas Pipeline Market Drivers * Increase in incidences of PTCL, rising investment for the development of advanced technologies, surge in government initiatives to promote research and awareness about the disease are some of the important factors that are fueling the Peripheral T Cell Lymphomas Market. Peripheral T Cell Lymphomas Pipeline Market Barriers * However, high cost associated with the treatment, lack of skilled professionals for early diagnosis of the disease and other factors are creating obstacles in the Peripheral T Cell Lymphomas Market growth. Scope of Peripheral T Cell Lymphomas Pipeline Drug Insight * Coverage: Global * Key Peripheral T Cell Lymphomas Companies: HUYA Bioscience International, Applied Therapeutics, Autolus, Akeso Biopharma, Astex Pharmaceuticals, Secura Bio, Innate Pharma, Dizal Pharmaceutical, CSPC ZhongQi Pharmaceutical Technology, and others * Key Peripheral T Cell Lymphomas Therapies: HBI-8000, AT-104, Auto 5, AK 104, Tolinapant, Duvelisib, Lacutamab, AZD 4205, Mitoxantrone liposomal, and others * Peripheral T Cell Lymphomas Therapeutic Assessment: Peripheral T Cell Lymphomas current marketed and Peripheral T Cell Lymphomas emerging therapies * Peripheral T Cell Lymphomas Market Dynamics: Peripheral T Cell Lymphomas market drivers and Peripheral T Cell Lymphomas market barriers Request for Sample PDF Report for Peripheral T Cell Lymphomas Pipeline Assessment and clinical trials [ https://www.delveinsight.com/sample-request/peripheral-t-cell-lymphomas-ptcl-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr ] Table of Contents 1. Peripheral T Cell Lymphomas Report Introduction 2. Peripheral T Cell Lymphomas Executive Summary 3. Peripheral T Cell Lymphomas Overview 4. Peripheral T Cell Lymphomas- Analytical Perspective In-depth Commercial Assessment 5. Peripheral T Cell Lymphomas Pipeline Therapeutics 6. Peripheral T Cell Lymphomas Late Stage Products (Phase II/III) 7. Peripheral T Cell Lymphomas Mid Stage Products (Phase II) 8. Peripheral T Cell Lymphomas Early Stage Products (Phase I) 9. Peripheral T Cell Lymphomas Preclinical Stage Products 10. Peripheral T Cell Lymphomas Therapeutics Assessment 11. Peripheral T Cell Lymphomas Inactive Products 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Peripheral T Cell Lymphomas Key Companies 14. Peripheral T Cell Lymphomas Key Products 15. Peripheral T Cell Lymphomas Unmet Needs 16 . Peripheral T Cell Lymphomas Market Drivers and Barriers 17. Peripheral T Cell Lymphomas Future Perspectives and Conclusion 18. Peripheral T Cell Lymphomas Analyst Views 19. Appendix 20. About DelveInsight About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Contact Person: Gaurav Bora Email:Send Email [ https://www.abnewswire.com/email_contact_us.php?pr=peripheral-t-cell-lymphomas-pipeline-2024-clinical-trials-assessment-fda-approvals-therapies-and-key-companies-involved-by-delveinsight-celleron-therapeutics-myeloid-therapeutics-astex-pharma ] Phone: +14699457679 Address:304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website: https://www.delveinsight.com/ This release was published on openPR.
MAGYAR BANCORP, INC. DECLARES SPECIAL CASH DIVIDEND
- Previous:
- Next: super ace secret
